Diagnosis and Management of Non–Kaposi Sarcoma Dermatologic Conditions in People With HIV

Assessment of Needs

Dermatologic conditions remain common among people with HIV (PWH) and may present with atypical features, diagnostic uncertainty, or management challenges related to immune status, antiretroviral therapy regimens, and patient comorbidities. This webinar will go beyond Kaposi sarcoma (KS) to review the diagnosis and management of non-KS dermatologic conditions in PWH, highlighting common and clinically significant presentations, key diagnostic considerations, and evidence-based treatment strategies to support patient care.

Learning Objectives

Upon completion of this activity, participants will be able to:

• Describe the features of common and clinically significant non–KS-related dermatologic conditions in PWH, such as herpes simplex, psoriasis, human papilloma virus, and tinea
• Utilize evidence-based diagnostic and management strategies for dermatologic conditions in PWH, including treatment considerations related to immune status and antiretroviral therapy regimens
• Integrate patient-centered approaches to improve outcomes for PWH experiencing dermatologic conditions

Registration

Who Should Attend

This webinar is designed for clinical decision makers who are actively involved in HIV care and research, including physicians, physician assistants, nursing professionals, pharmacists, and other health care professionals.

Individual registration is required in order to receive CME credit or a certificate of participation.

Registration closes on Tuesday, July 28, 2026, 10:30 AM (PT).

For more information or questions, please contact the registration department at registration@iasusa.org or 415-544-9400.

Conflicts of Interest

In the interest of maintaining the independence of its continuing medical education (CME) activities, the International Antiviral Society–USA (IAS–USA) requires all persons with control of educational content (eg, faculty, Scientific Leadership Board, Governance Board, and program planner) to disclose any financial relationships with ineligible companies (previously defined as “commercial interests”) that they have had within the past 24 months. Any real or apparent conflicts of interest of those parties are resolved and mitigated prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in IAS–USA CME activities. 

The Accreditation Council for Continuing Medical Education (ACCME) defines ineligible companies as “those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.”

IAS–USA will identify and resolve ahead of time any possible conflicts of interest that may influence CME activities with regard to exposition or conclusion. Information about financial relationships with ineligible companies for the presenter and planners/reviewers is below and in the slides prior to the presentation of educational content.

Presenter

Dr Maurer reported no financial relationships with ineligible companies. (Updated March 30, 2026)

Moderator

Dr Freeman reported receiving consulting or advisor fees from L’Oreal Dermatologic Beauty. (Updated July 7, 2025)

Planner/Reviewer

Planner/Reviewer 1 reported no relevant financial relationships with ineligible companies. (Updated March 30, 2026)
Planner/Reviewer 2 reported no relevant financial relationships with ineligible companies. (Updated May 19, 2026)

COW Board

The financial relationships of the COW Board can be found here: https://www.iasusa.org/activities/cases-on-the-web/about-cows/cow-webinars-editorial-board/